Comprehensive DNA Methylation Profiling in Crohn's Disease
NCT ID: NCT03272152
Last Updated: 2017-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
14 participants
OBSERVATIONAL
2017-01-01
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Expression in Inflammatory Bowel Disease
NCT01171872
Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas
NCT04113733
Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease
NCT04088773
Endomicroscopy in IBD Patients
NCT01417728
Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel
NCT00587210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inflamed CD group
Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
Genome-wide DNA methylation
Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Non-inflamed CD group
Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
Genome-wide DNA methylation
Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Control group
Control ileal mucosa was obtained from healthy patients
Genome-wide DNA methylation
Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genome-wide DNA methylation
Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Under treatment of immunomodulators, biologic agents or steroids
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinling Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianan Ren
Director of General Surgery Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jinling Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20170808
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.